CareCloud Misses Q1 EPS Despite Revenue Beat

Forward-Looking Analysis

Analyst projections for CareCloud’s fiscal second quarter of 2026 indicate a continued trajectory of earnings expansion, with consensus estimates suggesting a year-over-year earnings growth rate of 13.89%. The market anticipates the company’s earnings per share to increase from $0.36 in the prior period to $0.41. This positive outlook is underpinned by the company’s valuation metrics, which currently trade at a Price-to-Earnings (P/E) ratio of 22.18. This multiple is notably lower than the broader market average of approximately 46.01 and significantly below the Healthcare sector average of 282.25, suggesting relative undervaluation. Furthermore, the Price-to-Book (P/B) ratio stands at 1.74, a figure generally considered indicative of reasonable valuation relative to the company’s assets and liabilities. Market sentiment reflects this potential, with a consensus price target of $3.25, implying approximately 33.2% upside from the recent trading price of $2.44. The analyst consensus rating is a "Hold," derived from one buy rating, two hold ratings, and no sell ratings. Despite the modest earnings growth forecast, short interest has increased by 13.97% recently, and the news sentiment score of 0.07 remains significantly lower than the healthcare sector average of 0.73, indicating cautious investor sentiment despite the fundamental earnings projections.

Historical Performance Review

In the first quarter of 2026, CareCloud reported total revenue of $31.27 million, surpassing analyst estimates of $30.51 million. The company generated a gross profit of $14.42 million during this period. However, profitability metrics showed mixed results, with net income recorded at $922,000. Consequently, the earnings per share (EPS) for Q1 2026 were reported at -$0.01, which represented a miss against the consensus estimate of $0.06, highlighting ongoing challenges in translating top-line growth into consistent bottom-line profitability.

Additional News

CareCloud recently announced it will report its second quarter 2026 results on August 6, 2026. Prior to this, the company amended its credit agreement to refine financing terms, signaling adjustments to its capital structure. In a significant operational development, Empower, a subsidiary of CareCloud, assisted a wound-care provider in reversing more than $1 million in alleged overpayments, demonstrating the efficacy of its revenue cycle management solutions. Governance updates include the re-election of Mahmud Haq and Cameron Munter during the 2026 Annual Shareholders’ Meeting. However, the company faced reputational challenges after notifying hundreds of thousands of individuals that hackers had stolen medical records, a breach that occurred in late July. Despite these headwinds, the stock experienced minor positive movement, rising 0.5% in late July, while maintaining a healthy short interest ratio of 2 days to cover. Insider ownership remains robust at 14.80%, with no insider buying or selling activity recorded in the past three months, while institutional ownership stands at 10.16%.

Summary & Outlook

CareCloud demonstrates solid top-line growth potential with a 13.89% projected earnings increase and a P/E ratio of 22.18, offering value relative to sector peers. However, the Q1 2026 EPS miss and a negative EPS figure of -$0.01, despite revenue beating estimates, highlight persistent margin compression and operational inefficiencies. The recent data breach and low news sentiment score introduce significant reputational and regulatory risks that could impact future customer acquisition and trust. While the consensus price target suggests upside, the "Hold" rating reflects uncertainty. The outlook remains neutral to cautiously bearish in the short term due to execution risks and security concerns, though long-term growth drivers in healthcare IT remain intact. Investors should monitor the Q2 results for evidence of margin stabilization and effective breach mitigation.